一个真实世界的药监测研究FDA不良事件报告系统事件对obeticholic酸
Le Hai1, Jiaojiao Wu2, Xiaohong Pan2
1Hunan Drug Inspection Center, Changsha, Hunan, China.
这项研究使用现实数据确定了105个对obeticholic acid (OCA) 的不良药物反应信号,其中46个新信号不在产品标签上. 建议加强监测,以使OCA在临床上更安全地使用.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 现实世界的证据.
背景情况:
- 肥酸 (OCA) 用于治疗肝脏疾病.
- 现实世界的药物不良反应 (ADRs) 需要调查.
- 美国FDA的不良事件报告系统 (FAERS) 数据库是一个宝贵的资源.
研究的目的:
- 为了挖掘OCA的现实世界药物不良反应.
- 为了识别OCA的新不良反应信号.
- 为OCA提供安全和合理的临床使用提供参考资料.
主要方法:
- 从FAERS (2016年第二季度2023年第三季度) 提取OCA不良事件报告.
- 应用多种统计方法进行信号检测 (PRR,ROR,BCNN,MGPS).
- 信号强度和特征的分析.
主要成果:
- 收集了5661份与OCA相关的不良事件报告.
- 确定了105个不良反应信号,其中包括46个新信号.
- ,疲劳和便秘是常见的不良事件;异常的肝酶是关键信号.
结论:
- 药监测研究强调需要加强对OCA的临床监测.
- 识别的信号为有效的药物监测提供了关键数据.
- 这些发现支持OCA的合理临床药物治疗实践.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
Drug Regulation
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Direct-Acting Cholinergic Agonists: Pharmacokinetics
